Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (7748)	10/1/2001 9:39:48 PM
From: Montana Wildhack	Read Replies (2) \| Respond to of 14101

"..owing to what appears to be a wide variation in adherence to the regulations under the Mutual Recognition Procedure." My goodness I dislike beaurocracy. Nice job MCA on approving - not good on getting the Mutual Recognition Agreement part done for us. Britain was our agent in this and got pie in the face when asked by Britain to follow the MRA on a drug they had already approved. We've tripled our approved markets to $1 billion US in 6 countries with no rejections yet. I think I'll go to bed early to celebrate. Show the revenue so far Rebecca and it might be a good time for some revenue guidance from the UK.

To: Cal Gary who wrote (7748)	10/2/2001 1:20:20 PM
From: Joe Krupa	Read Replies (2) \| Respond to of 14101

Cal, from the nr: "In order to shorten approval times in the remaining member states, we have elected to deal with each state individually . . ." I believe that this decision must have been made in consultation with a marketing/dist partner. The logistics of different bureaucracies and languages in each country would necessitate the expertise of a partner with experience in each of those countries. I don't think Dimethaid would have chosen to go this route alone. That's my logical deduction, but of course I may be wrong. joe